Clinical Trial Update: Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab in combination with Inlyta for fumarate hydratase-deficient renal cell carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fumarate Hydratase Deficiency
• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• Sintilimab (sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Carcinoma, Renal Cell, Fumarate Hydratase Deficiency | Phase 2 | Status: ACTIVE_NOT_RECRUITING